Since macrophages play essential roles in the balance between fibrogenesis and regression and PPARγ agonists have been proven to reduce experimental liver fibrosis [23,36,37], we then evaluated the potential therapeutic utility of macrophage-targeted DGNS-GW in ECM remodeling in liver fibrosis. This evidence concerns the gene MASTL and Hepatic fibrosis.